臨床障害治療の世界市場：現状分析・予測（2022年～2028年）

世界の臨床障害治療の市場規模は、精神的・心理的疾患の有病率と同様に、思春期の薬物依存症が世界的に増加しているため、約6％で安定的に成長すると予測されています。また、多くの病院、クリニック、医療機関が、臨床疾患の適切な治療法について一般の人々を教育するキャンペーンを実施しており、近い将来、市場に大きな成長の可能性をもたらす見込みです。

当レポートでは、世界の臨床障害治療市場について調査分析し、セグメント別・地域別の市場洞察、市場力学、市場動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 市場イントロダクション

第2章 調査手法・前提条件

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 臨床障害市場に対するCOVID-19の影響

第6章 臨床障害市場収益（2020年～2028年）

第7章 市場洞察：薬剤クラス別

• 抗うつ薬
• 抗けいれん薬
• 抗不安薬
• 非定型抗精神病薬
• ノルアドレナリン作動薬

第8章 市場洞察：症状別

• 不安
• うつ

第9章 市場洞察：薬剤流通経路別

• 院内薬局
• 小売薬局
• オンライン薬局

第10章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• その他の地域

第11章 臨床障害：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第12章 臨床障害：市場機会

第13章 臨床障害：市場動向

第14章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第15章 バリューチェーン分析

第16章 価格分析

第17章 戦略的イニシアチブ

第18章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第19章 企業概要

• Universal Health Services, Inc
• CareTech Holdings Plc
• Behavioral Health Network, Inc
• Pfizer Inc
• GSK Plc
• Eli Lilly and Company
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• VistaGen Therapeutics, Inc

第20章 免責事項

Clinical Disorder treatment are focused on the diagnosis and treatment of psychiatric and psychological disorders. The main areas focus on mood disorders, anxiety disorders, obesity and eating disorders, addictions, and psychosomatic disorders. This illness can affect anyone, and of any age. This disorder is treatable. According to a statistical report by Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. This is in turn projected to offer abundant growth opportunities.

The clinical disorder treatment market is expected to grow at a steady rate of around 6% owing to the increasing use of adolescent substance addiction is on the rise globally, as is the prevalence of mental and psychological illnesses. Additionally, a lot of hospitals, clinics, and healthcare organizations are running campaigns to educate the general people about the proper course of treatment for clinical diseases. In turn, this is anticipated to provide the market with a wealth of growth potential in the near future.

Based on drug class, the market is segmented into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents. The antidepressants category held a significant share in 2020. An increasing number of candidates and product approvals of antidepressants will boost the market segment growth in the future due to rising hospital visits. Recently, the Food and Drug Administration (FDA) authorized two brand-new antidepressants that offer innovative methods for treating depression: esketamine and brexanolone.

Based on the indication, the market is categorized into anxiety and depression. This is mainly due to the influence of COVID-19 on the world which has been unparalleled and astounding, with increased demand shocks for anxiety disorders and depression treatment goods throughout all regions during the pandemic. During this time people are largely exposed to anxiety disorder. In addition, collaborative efforts by healthcare companies, NGOs, and government initiatives spreading awareness have become another factor in demand.

Based on the drug distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is predicted to grow at the fastest rate among all medication distribution channels over the course of the projection year.

For a better understanding of the market adoption of the clinical disorder treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market in North America is anticipated to gain the major proportion throughout the projection period owing to the region's high healthcare spending and growing awareness of the signs and symptoms of clinical illnesses. Additionally, in the APAC region it is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to growing incidences of substance abuse among teenagers and adults, in the countries like India and China. In 2019, South Asia regions witness approximately 30 million people is exposed to cannabis and 22 million people consuming opioids. In the upcoming years, it is also anticipated that the region's industry will increase due to the strong presence of key market players.

Some of the major players operating in the market include: Universal Health Services Inc, CareTech Holdings plc, Behavioral Health Network Inc, Pfizer Inc, GSK plc, Eli Lilly and Company, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc and VistaGen Therapeutics Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Clinical Disorder Treatment Market
• 2.2. Research Methodology of the Clinical Disorder Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CLINICAL DISORDER MARKET

6 CLINICAL DISORDER MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG CLASS

• 7.1. Antidepressants
• 7.2. Anticonvulsants
• 7.3. Anxiolytics
• 7.4. Atypical Antipsychotics
• 7.5. Noradrenergic agents

8 MARKET INSIGHTS BY INDICATION

• 8.1. Anxiety
• 8.2. Depression

9 MARKET INSIGHTS BY DRUG DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacy
• 9.2. Retail Pharmacy
• 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. USA
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 CLINICAL DISORDER MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 CLINICAL DISORDER MARKET OPPORTUNITIES

13 CLINICAL DISORDER MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INITIATIVES

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. Universal Health Services, Inc
• 19.2. CareTech Holdings Plc
• 19.3. Behavioral Health Network, Inc
• 19.4. Pfizer Inc
• 19.5. GSK Plc
• 19.6. Eli Lilly and Company
• 19.7. AstraZeneca Plc
• 19.8. Bristol-Myers Squibb Company
• 19.9. Johnson & Johnson Services, Inc
• 19.10. VistaGen Therapeutics, Inc

20 DISCLAIMER